Platinum-Resistant Ovarian Cancer

A Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen (innovaTV 208)

Women with platinum resistant ovarian cancer are asked to participate in a research study being conducted by Icahn School of Medicine at Mount Sinai.

You may be eligible to participate in this study if you:

  • Are a female at least 18 years of age or older
  • Have histologic documentation of epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer

You may not participate in this study if you:

  • Have primary platinum-refractory disease, defined as disease progression within 2 months of completion of first line platinum-based therapy
  • Have had gastrointestinal obstruction within the past 6 months or who currently require parenteral nutrition
  • Have known past or current coagulation defects leading to an increased risk of bleeding
  • Have clinically significant cardiac disease
  • Have active ocular surface disease
  • Have ongoing, acute, or chronic inflammatory skin disease
  • Have uncontrolled tumor-related pain
  • Have Inflammatory lung disease requiring chronic medical therapy
  • Have Grade 3 or higher pulmonary disease unrelated to underlying malignancy
  • Have Grade >1 peripheral neuropathy
  • Have inflammatory bowel disease including Crohn’s disease and ulcerative colitis
  • Are pregnant, breastfeeding or plan to become pregnant

Contact Information
Martina Kracikova, PhD, Study Coordinator
One Gustave L. Levy Place, Box 1170
New York, New York 10029
Phone: 212 824 7859